MED12 mutations, which occur in up to 80% of leiomyomas, are associated with abnormal activation of Wnt/β-Catenin signaling, sex steroid receptor signaling, and increased expression of genes related to cell proliferation and fibrosis [4,7,8]. Here, MED12 is linked to leiomyoma.